Genomics Is Changing the Rules for Underwriting Breast Cancer Patients
We have made great progress in the battle against breast cancer: improved screening and treatment have produced a 30% reduction in mortality over the last two decades. Better still, continued advances in genomics are opening entirely new possibilities that hold the promise of not only improved outcomes, but an eventual cure. For life and health insurers, it is time to reexamine how we underwrite applicants with a history of breast cancer.
Presentations from the 2016 SEHOUA Meeting
Slides from the 2016 SEHOUA Meeting have been posted. They include:
- Betsy Sears – “Young Kids, Old Bodies”
- Dr. Stout – “Drugs and Alcohol – The Landscape”
- Dr. Titcomb - “Red Cell Distribution Width (RDW): An Underappreciated Marker for Increased Mortality
- Mike Clift – “Motor Vehicle Reports and Driving Criticism Trends, Technology and Terminology”
- Dr. Greene - "Prostate Cancer: A Decade of Change"
- Dr. Dave Rengachary - “Advances in Multiple Sclerosis”
- Dr. Rooney – Genetics: A Discussion of How our Genes Impact Mortality”
- Ron Schaber, Philip R. Murphy and Greg Brandner - “Big Data Today and Tomorrow – the drive toward fully underwritten pricing”
Is Genetic Testing Good for the Insurance Industry?
Genetic testing is nothing new. It started back in 1822 with Gregor Mendel, the founder of the modern science of genetics, and his work on heredity.
RGA ReFlections May 2016 Issue
This edition of ReFlections contains an in-depth review of the role of genetics in the rapidly changing diagnostic criteria, risk stratification, and treatment of individuals with chronic lymphocytic leukemia (CLL). RGA also discusses the relatively new but increasingly popular Cancer Reimbursement product and its design, underwriting and claims issues. ReCite, a medical literature review section, has articles of interest to both underwriters and medical directors.
In the next decade, genetic tests may become significant and cheap enough that advisers begin suggesting insurance customers test prior to applying for insurance cover. Will consumer behavior change as genetic testing becomes more accessible?
Genetic Testing - Why Insurers Must Stay Tuned In (Gen Re)
Genomics is at the forefront of a technological revolution in biomedicine and healthcare through which personalised treatment is fast becoming a reality. Genomics will improve care across a range of health problems and allow more targeted therapy. If insurance is indeed a pool into which participants pay sufficient to cover their risk, shouldn’t insurers have access to this genomic knowledge to use in equitable ways to benefit customers?